ATE543507T1 - Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung - Google Patents

Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung

Info

Publication number
ATE543507T1
ATE543507T1 AT08847868T AT08847868T ATE543507T1 AT E543507 T1 ATE543507 T1 AT E543507T1 AT 08847868 T AT08847868 T AT 08847868T AT 08847868 T AT08847868 T AT 08847868T AT E543507 T1 ATE543507 T1 AT E543507T1
Authority
AT
Austria
Prior art keywords
sdf
composition containing
sustained release
release composition
present
Prior art date
Application number
AT08847868T
Other languages
English (en)
Inventor
Yasuhiko Tabata
Original Assignee
Ono Pharmaceutical Co
Yasuhiko Tabata
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co, Yasuhiko Tabata filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE543507T1 publication Critical patent/ATE543507T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08847868T 2007-11-07 2008-11-06 Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung ATE543507T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007289598 2007-11-07
PCT/JP2008/003204 WO2009060608A1 (ja) 2007-11-07 2008-11-06 Ｓｄｆ－１を含有してなる徐放性組成物

Publications (1)

Publication Number Publication Date
ATE543507T1 true ATE543507T1 (de) 2012-02-15

Family

ID=40625516

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08847868T ATE543507T1 (de) 2007-11-07 2008-11-06 Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung

Country Status (6)

Country Link
US (2) US8435953B2 (de)
EP (1) EP2218459B1 (de)
JP (1) JP5248519B2 (de)
AT (1) ATE543507T1 (de)
ES (1) ES2378918T3 (de)
WO (1) WO2009060608A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
EP2717894B1 (de) * 2011-06-07 2018-01-24 Mesoblast International Sàrl Verfahren zur reparatur von gewebeschäden mithilfe proteaseresistenter mutanten des stromazellenfaktors 1
US20140213524A1 (en) * 2011-08-23 2014-07-31 National University Corporation Hokkaido University Composition for regeneration of cartilage
US10639351B2 (en) 2013-10-22 2020-05-05 Helixmith Co., Ltd. Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
US10420818B2 (en) 2014-05-08 2019-09-24 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders
JP6532141B2 (ja) * 2014-09-26 2019-06-19 ヘリックスミス カンパニー リミテッド 肝細胞増殖因子及びストローマ細胞由来因子１αを用いた末梢動脈疾患の予防または治療用組成物
JP6581208B2 (ja) 2014-12-23 2019-09-25 イリヤ ファーマ エービー 創傷治癒の方法
US11229682B2 (en) 2017-03-30 2022-01-25 Wake Forest University Health Sciences Methods of treatment for kidney disease
WO2019032930A1 (en) * 2017-08-11 2019-02-14 Wake Forest University Health Sciences USE OF CXCL12 FOR THERAPY AFTER SURGERY OF THE PROSTATE
CN113144283B (zh) * 2021-04-26 2022-06-28 广东海洋大学 一种促进创伤愈合的TSCP-GelMA水凝胶及其制备和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2566798B1 (fr) * 1984-06-27 1986-12-12 Centre Nat Rech Scient Membrane porteuse de la luciferase pour le dosage de l'atp et son procede de production
JP3639593B2 (ja) 1993-05-31 2005-04-20 科研製薬株式会社 塩基性線維芽細胞増殖因子含有架橋ゼラチンゲル製剤
US6297337B1 (en) * 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
US20040253294A1 (en) 2001-07-18 2004-12-16 Yasuhiko Tabata Sustained release hgf hydrogel preparations
GB0201674D0 (en) * 2002-01-25 2002-03-13 Lorantis Ltd Medical treatment
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
JP2004123650A (ja) 2002-10-04 2004-04-22 Medgel Corp Ｎｋ４を含有する徐放性製剤
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
US20050271697A1 (en) 2004-06-07 2005-12-08 Conor Medsystems, Inc. Local delivery of growth factors for stem cell transplantation
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
EP1803464A4 (de) * 2004-09-17 2009-09-09 Cellgentech Inc Topisches präparat zur behandlung von hautgeschwüren
CN101227857B (zh) 2005-06-29 2011-10-19 电脑医师有限公司 具有导电桥的传感器组件
JP2007182407A (ja) * 2006-01-10 2007-07-19 Medgel Corp 徐放性ハイドロゲル製剤
JP2007289598A (ja) 2006-04-24 2007-11-08 Sanada Seiko Kk 食器収納器具

Also Published As

Publication number Publication date
ES2378918T3 (es) 2012-04-19
US20130243824A1 (en) 2013-09-19
JPWO2009060608A1 (ja) 2011-03-17
EP2218459B1 (de) 2012-02-01
EP2218459A1 (de) 2010-08-18
US20100267612A1 (en) 2010-10-21
US8435953B2 (en) 2013-05-07
WO2009060608A1 (ja) 2009-05-14
US9107953B2 (en) 2015-08-18
JP5248519B2 (ja) 2013-07-31
EP2218459A4 (de) 2011-06-01

Similar Documents

Publication Publication Date Title
ATE543507T1 (de) Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung
CY1118887T1 (el) Φαρμακευτικες συνθεσεις ελεγχομενης αποδεσμευσης οι οποιες περιλαμβανουν εναν εστερα φουμαρικου οξεος
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
MX2013001749A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
FR2892923B1 (fr) Utilisatiion des derives de l'acide para-coumarique ou para- hydroxycinnamique dans des compositions cosmetiques ou dermatologiques.
CL2011000663A1 (es) Compuestos derivados de n-heterociclil-2-sulfonil acetamida, moduladores del receptor cb2, utiles para el tratamiento del dolor, enfermedad pulmonar, reumatica, autoinmune, entre otras.
EA201000897A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
EP1841426A4 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
MY167123A (en) Conveniently implantable sustained release drug compositions
CL2011000867A1 (es) Formas cristalinas da, c y ii de (r)-5-[3-cloro-4-(2,3-dihidroxi-propoxi)- benz[z]ilideno]-2- ([z]- propilimino) -3-o- totil-tiazolidin-4-ona; composicion farmaceutica; y uso en el tratamiento o prevencion de rechazo de organos trasplantados, sindrome autoinmunitarios, asma, diabetes, cancer.
EP1874334A4 (de) Zusammensetzungen mit von beta 2-glykoprotein i stammenden peptiden zur prävention und/oder behandlung von gefässerkrankungen
AR050717A1 (es) Composiciones farmaceuticas
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
MX2009011316A (es) Derivados del acido lipoico.
TW200624128A (en) Gamma-polyglutamic acid (gamma-PGA, h form), gamma-polyglutamates and gamma-polyglutamate hydrogels
WO2006128100A3 (en) Chondrogenic compositions and methods of use
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
CY1117959T1 (el) 24-norudca για την αγωγη αυτοανοσης ηπατιτιδας
MX2009002787A (es) Composiciones y métodos para prevenir el cáncer con cupredoxinas.
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
ATE413865T1 (de) Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
JP2005527551A5 (de)